Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, ...

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it received a delisting ...

As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with ...

1Globe is led by Chiang Li and serves as an umbrella for his portfolio of life-science companies. Chiang Li represents a ...

Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 For any questions about the dividend payment process, shareholders should ...

BEIJING--(BUSINESS WIRE)--The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today ...

Board continues to govern Company and remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders Paying Agent has begun distributing ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.